

Patient Engagement Task Force

Patient
Engagement
Enabler
Resource

A practical guide to overcoming barriers to patient involvement in publication activities

Objectives

- Prepare different stakeholders for common challenges to involving patients in industry-sponsored publication activities.
- Outline key barriers and potential solutions, including relevant evidence and additional resources.

User Guide

- The information provided in this resource should not be considered a substitute for company policies or legal advice.
- This Patient Engagement Enabler Resource (PEER) has been designed using a 'question and answer' (Q&A) format to allow all content to be keyword searchable.
- The Q&As included in this PEER represent typical barriers encountered by each of the key stakeholders involved in engaging patients in publication activities:
 - **Patients (refers to patients, carers, advocacy groups, and patient representatives)**
 - **Sponsor company (refers to pharmaceutical, biotechnology and medical device companies)**
 - **MedComms Agency**
 - **Publishers**
- The contents page is organized by each of the stakeholder groups, listing key 'questions' and hyperlinking to the associated 'answers'.
- The home icon (top left) returns you to the contents page.
- A glossary of terminology and additional resources will be added in the next version.

Things to Consider

- This resource is for guidance only – please adapt it based on your specific circumstances.
 - The information provided should not be considered a substitute for company policies or legal advice.
- Factors to consider include:
 - Prior experience of sponsor and patient contributors in engaging patients in different types of publication activities
 - Differences between company codes of conduct and other standard operating procedures
 - Regional differences (compliance, company processes, etc.)
 - Therapy area and unmet needs
 - Product approval status

Contents

 Click on Q&As of interest and use the home icon to return to this page

Patient Q&As

Publication Process Understanding

Expectations and Timelines

Receiving Reimbursement

Unintegrated Perspectives

Sharing Personal Experiences

Diversity and Representation

Publisher Q&As

Lack of Editorial Board Support

Lack of Guidance

Sponsor Company Q&As

Lack of Understanding

Lack of Guidance

Lack of Alignment Between
Alliance Partners

Lack of Internal Alignment

PLS Compliance Concerns

Resource Implications

Inclusive Engagement

Identifying Opportunities

Reimbursement Considerations

Flexible Timelines

MedComms Agency Q&As

Lack of Decision Oversight

Lack of Guidance

Resource Implications

Negative Experiences

Identifying Opportunities

Lack of Interest

Unintegrated Perspectives

Promotional Perceptions

Patient Q&As

Patients refers to patients, carers, advocacy groups, and patient representatives.
The information provided in this resource should not be considered a substitute for company policies or legal advice.



Publication Process Understanding: I am not familiar with publication activities, scientific jargon, or my responsibilities as an author

- If you have no prior publications experience, **resources are available** to help you understand the publication development process and your role as a patient partner:
 - The [WECAN Patients in Publications training course](#)¹
 - The [Envision the Patient resources for Patient Authorship](#)²
 - The [ICMJE authorship criteria](#)³ and [how patients meet these criteria](#)⁴
- If you are **invited to author a publication**:
 - **Make the sponsor company aware** of any relevant details, such as your level of prior experience, whether you need any additional training and support, and what your preferred communication channels are.
 - Ensure there is an **authorship agreement** in place that clearly states your role and responsibilities.
 - Ask the sponsor company to provide **resources for onboarding patient authors**.
 - These should cover company-specific processes for developing publications, company codes of conduct, and glossaries and lexicons of any scientific terms or language you are likely to encounter during the project.
 - Resources should be accessible and written in plain language.

WECAN, Workgroup of European Cancer Patient Advocacy Networks.

1. WECAN. <https://wecanadvocate.eu/patients-in-publications/>. (Accessed 6 November 2025); 2. Envision the Patient. <https://www.envisionthepatient.com/patient-authorship>. (Accessed 6 November 2025); 3. ICMJE. <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>. (Accessed 6 November 2025);

4. ISMPP. <https://www.ismpp-newsletter.com/2020/05/26/patient-authorship-three-key-questions-answers-for-medical-communication-professionals-part-b/>. (Accessed 5 December 2025).



Expectations and Timelines: The publications process is time-consuming, and I'm worried that I won't be able to fulfil expectations and meet deadlines

- Ask the sponsor company to provide **clear descriptions of responsibilities and tasks** with corresponding **timelines** to make sure you are clear on expectations.
 - You can request flexibility and buffers in the timelines.
 - This can help you balance being a patient partner with other responsibilities and unexpected circumstances such as illness.
- Make sure the sponsor company confirms a **key point of contact** for you to liaise with.
 - Maintain clear and regular communication with this contact so they can guide you through the publication development process.
- Don't be afraid to **advocate for yourself** and speak up if the process becomes overwhelming or you need more time for tasks.



Receiving Reimbursement: I am concerned that the reimbursement I have been offered may impact government benefits or have tax implications

- Be aware than many companies have policies that don't allow reimbursement for authorship.
 - Refer to company policies and other relevant guidelines
- Accepting reimbursement is a personal decision based on your individual situation; Understand that your participation is valued regardless of whether you accept reimbursement
- If reimbursing patients, fair market value calculators can guide companies^{1,2}
- If you have **queries or concerns around reimbursement**, you can:
 - Refer to **general and country-specific guidelines** on patient involvement for information. Country-specific guidelines for patient engagement are available [here](#);³ these include the [EFPIA principles](#)⁴ in Europe, and [guidance from the NIHR](#)⁵ in the UK.
 - Ask your **key point of contact** to connect you with patient engagement team leads, or other relevant colleagues within the sponsor company.
 - Understand that sponsor companies do not provide personal tax advice. Instead, please refer to a country-specific tax advice charity or citizen's advice bureau, such as [TaxAid](#)⁶ in the UK and the [Taxpayer Advocate Service](#)⁷ in the US.
- Disclosure of any reimbursement is essential to ensure full transparency and maintain the integrity of the publication



Unintegrated Perspectives: I feel that my contribution to this publication has been separated out from the rest of the content

- Take time to understand at the outset **how your input will influence the paper**. For instance, you may be asked to contribute to a specific patient perspectives section, or your input may be integrated with that of the other authors.
 - Refer to codes of conduct or charters for roles and responsibilities.
 - There may also be limitations that need to be considered, such as journal instructions or reporting publication guidelines.
 - **Discuss any concerns** about your role with your key point of contact.
- Once publication development is underway, if you feel that **your contributions are not being taken into account, or your role is not what was originally communicated**:
 - **Raise your concerns as early as possible** in the publication development process.
 - Ideally, have these discussions during early author calls, or when you are reviewing the publication outline before the full version is drafted.
 - Maintain **regular communication with your key point of contact** to share your concerns, ensure your feedback is considered, and develop an action plan.
 - Remember that **you have the right to remove your name as an author** at any stage if you aren't happy with the process.



Sharing Personal Experiences: I have experienced personal frustrations in medical contexts, but I have been told that the publications process is not a place to vent these

- Keep the **objective of the collaboration and shared purpose** as the main focus.
- Understand agreed expectations regarding **appropriate and sensitive interactions and behaviors** for all parties from the outset.
 - Refer to codes of conduct or charters of roles and responsibilities to align on the scope of the publication process.
- Ask your point of contact if there is **an appropriate channel, support service, or time to discuss any personal frustrations or emotions** that may arise during publication discussions.



Diversity and Representation: I do not feel that I adequately represent the wider patient community in relation to this publication

- Remember that **no individual patient can be fully representative** of the entire patient population.
- Understand the **scope of the publication** and your role as a patient partner.
 - For some types of publication, you may be representing your own perspective.
 - If your role is to represent your wider community, you should consider the needs of this community and be able to blend your personal experiences with those of other individuals.
 - Regular interactions with other patients and patient organizations can support this.
- Before agreeing to be an author, have **early discussions with the sponsor company about your experiences** to help you both understand whether you are providing a relevant perspective.
 - The [IMI PARADIGM guidance](#) discusses skills and experiences that patient partners can bring to different types of patient engagement projects.¹
- Bear in mind that **companies may work with a range of authors**, including patients and healthcare professionals, to include diverse perspectives in a publication.

IMI, Innovative Medicines Initiative; PARADIGM, Patients Active in Research and Dialogues for an Improved Generation of Medicines.

1. IMI PARADIGM. <https://imi-paradigm.eu/PEtoolbox/identification-of-patient-representatives-bw.pdf>. (Accessed 6 November 2025).

Sponsor Company Q&As



Lack of Understanding: My company does not understand the value of involving patients in publications

- **Patient perspectives are relevant in most therapy areas.** Work with your team(s) to identify relevant potential opportunities to involve patients in publications – open a discussion by asking why your company are not interested.
- If your company has a **Patient Engagement team**, discuss how patient involvement can increase the impact of your publications and communicate this internally to effect change.
- Demonstrate **what competitors are doing** with patient engagement in the same therapy area.
 - Use **case studies** to show how patient involvement can lead to more impactful publications and publication plans.
- **Find relevant patients and patient organizations** that may be able to participate in publications development.



Lack of Guidance: My company does not have an established framework for involving patients in publications

- While your company may not involve patients in publications, patients may already be engaged in the clinical development process (e.g., to inform protocol/study design). **Connect with other internal teams to understand what level of patient engagement already exists elsewhere within your company**, and what framework might already be in place.
- If there is no framework available elsewhere in your company, **create a company-specific framework** by adopting or adapting existing guidance and relevant publications. These include:
 - The [2022 GPP guidelines](#)¹
 - The [ICMJE authorship criteria](#)²
 - The [GRIPP2 reporting guidelines](#)³
 - A 2025 patient-authored publication providing practical steps to advance patient authorship⁴
 - A 2025 article on facilitating patient involvement in publications⁵

ICMJE, International Committee of Medical Journal Editors; GPP, Good Publication Practice; GRIPP2, Guidance for Reporting Involvement of Patients and the Public, Version 2.

1. DeTora LM, et al. *Ann Intern Med*. 2023;176:eL220490; 2. ICMJE. <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>. (Accessed 4 November 2025); 3. Staniszewska S, et al. *Res Involv Engagem*. 2017;3:13; 4. Bharadia T, et al. *Patient*. 2025;18:403-414; 5. Cooksey K, et al. *BMC Med Res Methodol*. 2025;25:39.



Lack of Guidance: My company does not have an established framework for involving patients in publications (cont.)

- Collaborate with cross-functional colleagues such as Legal/Compliance and Patient Engagement to **co-create guidance documents**:
 - **Key topics** include identifying and engaging patient partners, authorship eligibility, and compensation policies
 - **Adapt publicly available documents** where possible, such as the [PFMD contract templates](#)¹
 - **Adapt existing company documents** where possible (e.g., an authorship agreement could be rewritten in plain language for patient authors)
 - Define **specific roles and responsibilities** for patients involved in publications in different capacities – as authors, reviewers or advisors
 - Ensure that all **externally facing plain language documents** undergo relevant cross-functional alignment before use, in consultation with compliance and legal colleagues
- **Build internal awareness** through existing training on ethical patient involvement, such as the [PFMD](#)² and [DIA](#)³ courses.
- Consider setting up a **dedicated Patient Engagement Team** to facilitate patient partnership in publications.
- **Make a start!** Identify an appropriate pilot project, collect feedback to demonstrate value and refine your framework.

DIA, Drug Information Association; PFMD, Patient Focused Medicines Development.

1. PFMD. <https://pemsuite.org/legal-and-contractual-tools/>. (Accessed 6 November 2025); 2. PFMD. <https://pemsuite.org/patient-engagement-training/>. (Accessed 6 November 2025);

3. DIA. <https://www.diaglobal.org/en/course-listing/certificate-program/patient-engagement>. (Accessed 6 November 2025).



Lack of Alignment Between Partners: My alliance partners do not have an established framework for involving patients in publications, or their framework is different to mine

- When working in collaboration with another company it is important to be aligned before involving patients in any publications
- Work with your publication counterparts to **align on processes and guidance before approaching any potential patient partners**. This aims to prevent any confusion.
- **Compare existing policies and frameworks** from alliance partners.
 - Leverage existing materials and identify any gaps.
 - Highlight any differences between materials and discuss these with compliance colleagues from both companies.
- **Co-create revised policies** that meet the needs of both alliance partners.
 - Ensure that all policies are approved by compliance and legal colleagues from both companies.
 - Ensure that the policies are also available in plain language.
- Ensure that **patient partners are clear about the aligned process** and their named key point of contact.
 - To prevent confusion during the development of a publication, identify **one key point of contact** who represents both alliance partners and takes overall responsibility for communicating with patient partners.
- **Document and share learnings** to continuously refine the alliance framework and support consistency in future projects.



Lack of Internal Alignment: There is limited collaboration between the Patient Engagement and Publications teams within my company

- **Establish a framework for collaboration** between Patient Engagement and Publications teams:
 - Identify key barriers to effective collaboration.
 - Establish a cross-functional working group to overcome these barriers.
 - Actions could include:
 - Defining clear roles, responsibilities, and shared objectives in relation to patient involvement
 - Ensuring all colleagues are trained on patient involvement and relevant internal/external guidance
 - Addressing compliance concerns
 - Establishing the need for further policies or guidance
 - Identifying where to involve patients in the publication lifecycle, including involvement in strategic publication planning where relevant
 - Raising awareness between functions of current and upcoming patient involvement activities
- Review where patients may already be engaged elsewhere within your company (e.g., to inform protocol/study design) and **what collaborations already exist with your Patient Engagement team:** leverage key learnings.
- Consider relevant metrics applicable across functions to measure the success and value of patient involvement.
 - [PFMD](#),¹ [IMI PARADIGM](#),² and the [ISMPP Patient Engagement Task Force](#)³ have developed guidance on metrics for patient engagement.

IMI, Innovative Medicines Initiative; PARADIGM, Patients Active in Research and Dialogues for an Improved Generation of Medicines, PFMD, Patient Focused Medicines Development.
1. PFMD. <https://pemsuite.org/monitoring-to-learn-tools/>. (Accessed 6 November 2025). 2. IMI PARADIGM. <https://imi-paradigm.eu/petoolbox/monitoring-evaluation/>. (Accessed 6 November 2025). 3. ISMPP. https://www.ismpp.org/assets/ISMPP%20PETF%20Impact%20Metric%20Tools_Final.xlsx. (Accessed 6 November 2025).



PLS Compliance Concerns: I am worried that PLS and PLSPs could be perceived as promoting to patients

- PLSs are summaries of scientific articles and congress abstracts **written in easy-to-read, non-technical language**¹ and are usually published within the article or congress poster.
- PLSPs are standalone, peer-reviewed articles summarizing one or more previously published articles in plain language.²
- PLSs and PLSPs do not introduce any new data.
- Publication of PLSs and PLSPs in the peer-reviewed medical literature has **increased exponentially** during the last decade.
 - PLS are encouraged by the 2022 GPP guidelines.³
- **PLSs and PLSPs aim is to democratize data** by making the medical literature accessible to non-technical audiences, including non-specialist healthcare professionals, patients, and the public.
 - Patients are increasingly involved in authoring or collaborating on PLS and PLSPs, both during development and peer review.
- **PLSs and PLSPs are not promotional materials.**
 - PLSs and PLSPs are based on peer-reviewed publications, which by definition are robust, credible and balanced information sources without promotional intent.
 - In common with their source publications, PLS and PLSPs published in medical journals are developed in line with GPP guidelines and undergo rigorous peer review to ensure accuracy and quality.
- **Some journals develop their own PLSs** for medical publications.
 - Note that some journals do not allow PLSPs to be published in a different journal if a PLS accompanies the main article.

When developing PLS/PLSPs refer to your company policies and any country-specific guidance

GPP, Good Publication Practice; PLS, plain language summary; PLSP, plain language summary publication.

1. Dorma L, et al. *Res Involv Engagem*. 2022;8:23. 2. Taylor and Francis. <https://files.taylorandfrancis.com/plsp%20guidelines%20for%20authors.pdf>. (Accessed 6 November 2025).

3. DeTora LM, et al. *Ann Intern Med*. 2023;176:eL220490.



Resource Implications: I have inadequate budget, staffing, and time to involve patients in publication development

- **Identify publication activities that would benefit most** from patient engagement.
- Embed patient involvement within the publication plan **as early as possible**, enabling budget and resource to be allocated to it.
 - This can help to establish the value of patient involvement and avoid it being seen as a 'nice to have' tactic in response to a gap in data flow.
 - When selecting tactics, consider the target audiences and the intent of the tactic (the 'so what'), as well as what could also be used by other internal teams.
- Identify quick wins that **show the value of communicating in lay terms** to ensure plans for patient involvement in publication development are implemented.
 - For example, when developing content for presentations at congresses, include a PLS on a slide at the end of a presentation or as part of a poster, as well as a PLS infographic behind a QR code; then, use audience feedback and usage data to demonstrate the value of communicating in a different way to help to get buy in on other tactics that clearly communicate on a key subgroup where a patient partner would be required (e.g., a PLSP).
- Ensure you have robust processes in place to make patient involvement **as efficient as possible** to minimize burden on internal stakeholders.



Inclusive Engagement: I am uncertain how to tailor my approach for the specific needs of the patients I am partnering with

- **Ask your Patient Engagement team** for their advice and consider collaborating with them to host an advisory board to assess where patient involvement in publications could add value.
- Create a **culture where patients feel supported and comfortable** to express their views and ask questions.
 - Ask patients what they would like to see put in place to feel supported.
- Offer **flexibility within your process** to consider individual needs, for example adaptable timelines.
 - Identify one key point of contact who takes overall responsibility for communicating with patient partners.
- Ensure **effective communication**.
 - Use plain language and avoid jargon so all communication is understandable.
 - Develop internal resources, such as a therapy area-specific patient lexicon, to support all colleagues to use appropriate language.
- Offer **flexible communication channels** to meet individual preferences while balancing resources and other goals.
 - Virtual meetings, email correspondence, text messaging, etc., are regular communication options for informal catch-ups and project correspondence.
- **Refine your approach using feedback** from patients and evaluate the quality of patient involvement in your project. For example, using the [PFMD Patient Engagement Quality Guidance](https://patientfocusedmedicine.org/pegg/patient-engagement-quality-guidance.pdf)¹ and a [published patient author experience tool](#).²

PFMD, Patient Focused Medicines Development.

1. PFMD. <https://patientfocusedmedicine.org/pegg/patient-engagement-quality-guidance.pdf>. (Accessed 6 November 2025); 2. Arnstein L, et al. *Res Involv Engagem*. 2020;24:34.



Identifying Opportunities: I am unable to identify opportunities to involve patients in publication activities, or to identify the right patients to partner with

- **First identify topics for which a patient perspective would add value.**
 - Understanding unmet treatment needs; what it's like to live with the condition; how clinical data translate into a real-life setting; review of PROs; impact of study endpoints that have a meaningful impact to patients (vs what an HCP may consider important); impact to care partners and the needs of care partners.
- **Then identify key touchpoints throughout the publication lifecycle** where patient perspectives could add value:
 - These could include concept development, authorship, writing and/or reviewing PLS, and dissemination planning.
 - Use patient perspectives to augment your publication plan, by including patients in publication steering committees and working groups.
- **If you're struggling to find the right patients to partner with:**
 - Define the **relevant skills and level of experience** that will be required.
 - Leverage **existing relationships**.
 - Identify and work with internal stakeholders who have established external relationships with individual patients and/or patient organizations, such as the Patient Engagement and Medical Affairs teams.
 - Build **new relationships**.
 - Guidance is available from IMI PARADIGM on identifying patient representatives.¹
 - Once you have **identified patient partners**, ensure you understand their motivations for participation (including previous experience working with industry), and their practical ability to contribute.

HCP, healthcare professional; IMI, Innovative Medicines Initiative; PARADIGM, Patients Active in Research and Dialogues for an Improved Generation of Medicines; PRO, patient reported outcome.

1. IMI PARADIGM. <https://imi-paradigm.eu/PEtoolbox/identification-of-patient-representatives-bw.pdf>. (Accessed 6 November 2025).



Reimbursement Considerations: My company has no clear policy related to compensation of patient contributors

- Compensation for byline authorship may introduce perceived or actual bias and affect trust in publications
- Compensation may support patient engagement activities that contribute to publication development; however, authorship itself should not be purchased, incentivized, rewarded or made contingent upon compensation
- Any compensation should not be contingent on authorship status or authorship decisions, while being appropriate to the contribution and fully disclosed
- Approaches should align with established authorship criteria (e.g., ICMJE¹), GPP 2022 recommendations,² and any relevant company policies and/or applicable laws
- Compensation arrangements and the activities for which compensation may be provided should be made clear and in advance with patient partners
- Resources such as PFMD³ and the NHC⁴ may provide additional information regarding patient engagement compensation and implementation considerations

ICMJE, International Committee of Medical Journal Editors; GPP, Good Publication Practice; NHC, National Health Council; PFMD, Patient Focused Medicines Development.

1. ICMJE. <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>. (Accessed 4 November 2025);

2. DeTora LM, et al. *Ann Intern Med*. 2023;176:eL220490. <https://www.acpjournals.org/doi/10.7326/M22-1460> 3. PFMD. <https://pemsuite.org/fmv/>. (Accessed 6 November 2025).

4. NHC. <https://nationalhealthcouncil.org/access-the-fmv-calculator>. (Accessed 6 November 2025).



Flexible Timelines: The patients I am partnering with are facing personal issues such as illness, which could affect our ability to meet project deadlines

- Consider how to **adapt your project timelines to accommodate patient needs** while still meeting your objectives – patient centricity is key.
- **Communicate sensitively** around deadlines.
 - Consider requesting alternative contact information from the patient, such as contact details for their next of kin.
- Build additional **flexibility into timelines**.
 - Include buffer time to compensate for unexpected circumstances.
- Build **flexibility into tasks**.
 - Instead of requiring patient partners to provide feedback via email or a publication management system, consider different ways in which they can provide their feedback – virtual meetings, email correspondence, text messaging, etc.
 - Consider how to make contributions more manageable, for example breaking larger tasks down into smaller ones.
- **Emphasize that all contributions are valuable**, regardless of scale or timing.
 - If patient partners are unable to review every draft, make reasonable adjustments/concessions that align with patient needs whilst adhering to authorship criteria.
 - If patient partners cannot approve a final version of the publication because of a serious worsening of their condition or death, adopt the procedure used for any author who is unable to approve the final version.

MedComms Agency Q&As



Lack of Decision Oversight: Decisions on patient engagement are made by my client; my agency is not involved in the process

- You have a role in making sure your client **considers engaging patients** in publication activities.
 - As early as possible, ask if the client company has a patient engagement framework in place, and if patients have already been engaged in the clinical development program (e.g., provided input into a protocol design or participated in a patient insights activity).
 - Encourage them to maximize patient involvement in line with their company framework.
- Make your client aware of **your patient engagement capabilities**.
 - You may be acting as an intermediary between the client and patient partners, helping to guide ethical collaboration and inclusive publication practices.
- **Educate clients on the value** of patient involvement in publications.
 - Share [evidence on the benefits of patient involvement in publications](#).¹
 - Provide case studies that demonstrate successful patient involvement in publications, such as examples from the [PFMD Book of Good Practices](#).²



Lack of Guidance: My client does not have an established framework for involving patients in publications

- Ensure you and your colleagues have the **skills to support patient involvement** in the absence of client frameworks.
- Make the client **aware of publicly available resources** and relevant patients/patient organizations who may be able to support framework development.
 - Resources include the [2022 GPP guidelines](#),¹ the [ICMJE authorship criteria](#),² the [GRIPP2 reporting guidelines](#),³ a 2025 [patient-authored publication providing practical steps to advance patient authorship](#),⁴ a 2025 [article on facilitating patient involvement in publications](#)⁵ and [PFMD contract templates](#).⁶
- Work with the client and relevant patients/patient organizations to **co-develop a framework** for patient engagement in publications.
- If the client has a Patient Engagement team, suggest that they **involve this team** in framework development.

ICMJE, International Committee of Medical Journal Editors; GPP, Good Publication Practice; GRIPP2, Guidance for Reporting Involvement of Patients and the Public, Version 2; PFMD, Patient Focused Medicines Development.

1. DeTora LM, et al. *Ann Intern Med*. 2023; 176:eL220490; 2. ICMJE. Available at: <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>. (Accessed 4 November 2025); 3. Staniszewska S, et al. *Res Involv Engagem*. 2017;3:13; 4. Bharadia T, et al. *Patient*. 2025; 18:403-414; 5. Cooksey K, et al. *BMC Med Res Methodol*; 25:39;

6. PFMD. <https://pemsuite.org/legal-and-contractual-tools/>. (Accessed 6 November 2025).



Resource Implications: My client is concerned that patient involvement will negatively impact publication timelines and budget

- Remember that the **benefits of patient involvement offset the potential impact** on budget, timelines and resources.
 - Potential benefits include greater relevance, clarity and accessibility of the publication, stronger trust with patient communities, and broader dissemination of the publication.
- Work with clients to understand budget needs associated with patient involvement, such as honoraria and support costs.
 - Where needed, share guidance on patient remuneration such as those from PFMD¹ and the NHC.²
- Involve patients and establish roles and responsibilities **as early as possible** in the publication process, to align expectations and minimize delays later.
 - Discuss typical publication timelines upfront to help manage both client and patient expectations.
- When **preparing the publication timeline**, ensure it facilitates patient involvement.
 - For example, allowing sufficient time to review materials and including buffer time for unexpected delays.
- **Communicate with the journal editor regarding timelines**, and keep them informed if extensions will be required, for example to manage revisions.

NHC, National Health Council; PFMD, Patient Focused Medicines Development.

1. PFMD. <https://pemsuite.org/fmv/>. (Accessed 6 November 2025); 2.NHC. <https://nationalhealthcouncil.org/access-the-fmv-calculator>. (Accessed 6 November 2025).



Negative Experiences: My client has had a previous negative experience in a patient engagement project

- Discuss with your client to understand **why their experience was negative**.
- Educate your client on the **benefits of patient engagement** in the publication lifecycle and provide published case studies highlighting the value.
- **Share your team's own experiences** of patient engagement in publications, demonstrating the feasibility.
- **Identify an internal company advocate** who has had a positive experience for your client to connect with.



Identifying Opportunities: I am struggling to find opportunities to discuss patient involvement in publications with my client

- Be aware that your client may be **familiar with certain activities in which to involve patients**, such as PLS and patient authorship, **but unaware of other activities such as** publication planning and steering committees.
- Educate your client on the **different opportunities to involve patients** throughout the publication lifecycle:
 - Help them to identify topics for which a patient perspective would add value: unmet needs; lived experience; meaningful endpoints, PROs; impact on/needs of carers.
 - Consider sharing slides and case studies on how this can be done for different activities, particularly for planning activities where the patient perspective tends to be overlooked, such as in steering committees.^{1,2}
- **Review existing publication plans** with your client to identify opportunities for patient involvement
 - Schedule a specific meeting to discuss these opportunities and clarify what they need from you.
- Proactively offer to address internal barriers by offering to talk to the relevant teams directly (such as Patient Engagement and compliance teams).
- Link the value of patient engagement with key performance indicators that your client is working towards.

PLS, plain language summary; PRO, patient-reported outcome.

1. Feighery L, et al. Medical Writing. 2020;29(4):32-38. 2. Wooley K, et al. Poster 90675 at DIA Global Annual meeting (Virtual): June 14-18, 2020.



Lack of Interest: My client is not interested in patient involvement in their specific therapy area

- Remember that **patient perspectives are relevant in most therapy areas**. It is your job to work with your client to identify the most relevant potential opportunities to involve patients in publications – open a discussion by asking why they are not interested.
- Use **case studies from other therapy areas** to show your client how patient involvement can lead to more impactful publications and publication plans.
- If the client company has a **Patient Engagement team**, suggest they connect with this team to discuss how patient involvement can support publications in their therapy area.
- Support your client to **find relevant patients and patient organizations** that may be able to participate in publications development.
- Demonstrate **what other companies are doing** with patient engagement in the same therapy area.



Unintegrated Perspectives: My client only asks patient authors to review sections of publications, leaving them separated from the author group

- **Encourage clients to involve patients from the outset.**
 - Use guidelines to support this suggestion, including GPP 2022, ICMJE authorship criteria, and other industry guidelines.
- Use client codes of conduct or charters of roles and responsibilities to **manage shared expectations** and encourage integration of patient authors.
- Ensure the **remit of patient engagement within the publication** is clear.
 - Obtain alignment at the publication outline stage.
- Provide **context and background** on the types of opportunities available to integrate the patient voice into publications, and any limitations or guidelines that need to be adhered to (e.g., journal instructions or reporting guidelines).
- Suggest **asking patient authors for feedback** on the process during and after publication development to improve future patient engagement.
 - For example, using the [PFMD Patient Engagement Quality Guidance](https://patientfocusedmedicine.org/peqg/patient-engagement-quality-guidance.pdf)¹ and a [published patient author experience tool](#).²

PFMD, Patient Focused Medicines Development.

1. PFMD. <https://patientfocusedmedicine.org/peqg/patient-engagement-quality-guidance.pdf>. (Accessed 6 November 2025); 2. Arnstein L, et al. *Res Involv Engagem*. 2020;24:34.



Promotional Perceptions: My client is concerned that involving patients in publication activities could be seen as promotional

- Remember that perceptions of promotion are valid and reflect a **broader industry tension between meaningful patient engagement and regulatory compliance**.
 - Sensitivities exist around accessibility of publications to broader audiences beyond specialist healthcare professionals.
- Show your client that you **understand the potential sensitivities** surrounding patient involvement in publication activities, especially when patients are using the sponsor's product or taking it in the context of a clinical trial.
- Share established **industry guidelines that support patient engagement** when it is transparent, well-documented, and scientifically grounded – [2022 GPP guidelines](#),¹ IFPMA,^{2,3} ABPI.⁴
- **Highlight the value of peer review** in ensuring robust, balanced, and accurate publications – all publications that go through peer review are by definition non-promotional.
- Make **clear recommendations** on how to avoid any potential promotional perceptions, such as:
 - Ensuring the patient's role in the publication is clearly and transparently defined and disclosed
 - Avoiding the use of promotional language
 - Include the compliance team in framework development
 - Inclusion of an internal compliance review step as part of the publication development process
 - Ensuring colleagues in commercial roles do not influence content development or approval of publications

1. DeTora LM, et al. Ann Intern Med. 2023;176:eL220490; 2. IFPMA. <https://www.ifpma.org/publications/ifpma-code-of-practice-2019/>. (Accessed 6 November 2025); 3. IFPMA. https://www.ifpma.org/wp-content/uploads/2020/03/20242003_IFPMA_NfG_Patient-and-Patient-Organization-Interactions.pdf. (Accessed 6 November 2025); 4. ABPI. https://www.abpi.org.uk/media/dj5dvske/11555-abpi_patient-sourcebook_aw_v2-2023.pdf. (Accessed 6 November 2025).

Publisher Q&As



Lack of Editorial Board support: My journal's Editorial Board/Editor-in-Chief doesn't agree with the inclusion of patient authors

- A publisher can **encourage the inclusion of patient authors** during discussions with a journal's Editorial Board/Editor-in-Chief (e.g., during Editorial Board meetings).
- **Provide relevant information** to the Editor-in-Chief/Editorial Board on patient authorship, including:
 - The **value that patient authorship brings** to publications (e.g., as lived experience experts), supported by industry guidelines (e.g., [GPP](#)¹)
 - How patient authorship is **compatible with existing journal authorship criteria**, such as [ICMJE](#)²
 - **Examples of other journals and publishers that have included patient authors**, demonstrating that this practice is increasingly accepted and feasible³
- **Emphasize the value proposition for the journal**, including improved relevance, transparency, trust, and alignment with funder, policy-maker and community expectations.
- **Reinforce that editorial processes are maintained**, with patient authors held to the same standards of disclosure, accountability, and ethical oversight as all other authors.

1. DeTora LM, et al. *Ann Intern Med*. 2023;176:eL220490; 2. Envision the Patient. <https://www.envisionthepatient.com/patient-authorship#resources>. (Accessed 6 November 2025); 3. Oliver J, et al. *Res Involv Engagem*. 2022;8(1):12.



Lack of Guidance: My journal/publisher does not have established guidelines for patient authors

- While your publishing organization/journal may not specifically mention patient authors within its guidelines, **much of the existing author guidance will be relevant**. Any new guidance should align with existing publisher policies on ethics, authorship, conflicts of interest, and DEI, rather than treating patient authorship as a separate or exceptional case.
- **Make use of existing industry guidance** rather than creating policies from scratch, adapting them to the journal's scope and audience.
- **Key resources include:**
 - The [GPP 2022 guidelines](#),¹ which explicitly address patient authorship and contributions
 - The [ICMJE](#) authorship criteria,² applicable to all authors regardless of background
 - The [GRIPP2](#) reporting guidelines,³ for transparent reporting of patient and public involvement
 - Recent publications offering practical insights into inclusive publication practices
- It may be useful to **develop FAQs** for internal editors, Editorial Board members, authors and reviewers, covering topics such as eligibility for authorship, disclosures, conflicts of interest, and compensation.
- **Engage with patients and/or patient organizations to co-develop guidance**, ensuring policies are practical and inclusive.

DEI, diversity, equity, and inclusion.

1. DeTora LM, et al. *Ann Intern Med*. 2023;176:eL220490. 2. ICMJE. <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>. (Accessed 6 November 2025); 3. Staniszewska S, et al. *Res Involv Engagem*. 2017;3:13; 4. ISMPP Patient Engagement. <https://www.ismpp.org/patient-engagement>. (Accessed 6 November 2025).